Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells 470 Shares of Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 470 shares of the company's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $251.37, for a total value of $118,143.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lai Wang also recently made the following trade(s):

• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The shares were sold at an average price of $266.40, for a total transaction of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78.

BeOne Medicines Trading Down 2.3%

Shares of NASDAQ:ONC traded down $5.70 during midday trading on Friday, hitting $247.08. 230,772 shares of the stock were exchanged, compared to its average volume of 298,435. The company has a market capitalization of $27.07 billion, a PE ratio of -66.42 and a beta of 0.30. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $141.31 and a twelve month high of $287.88. The firm has a 50 day simple moving average of $245.59. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. On average, equities research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Guggenheim lifted their price objective on shares of BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. TD Securities reiterated a "buy" rating and issued a $334.00 price target on shares of BeOne Medicines in a research report on Thursday, April 24th. JMP Securities set a $348.00 price objective on shares of BeOne Medicines in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. boosted their price target on BeOne Medicines from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, BeOne Medicines currently has a consensus rating of "Buy" and an average price target of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.